Sales of Biogen ’s costly new Alzheimer’s drug fall far short of expectations.

The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue for the rest of the year.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Drugs (Pharmaceuticals) Aduhelm (Drug) Alzheimer ' s Disease Medicare Biogen Inc Cleveland Clinic Blue Cross and Blue Shield Assn Food and Drug Administration Mount Sinai Medical Center Veterans Affairs Department Vounatsos, Michel Source Type: news